Lowest-Rated StocksLowest-RatedNYSE:NVO Novo Nordisk A/S (NVO) Stock Price, News & Analysis $39.12 +0.07 (+0.18%) Closing price 10/26/2026 03:59 PM EasternExtended Trading$38.74 -0.38 (-0.98%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Novo Nordisk A/S Stock (NYSE:NVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novo Nordisk A/S alerts:Sign Up Key Stats Today's Range$38.67▼$39.2450-Day Range$37.31▼$48.6552-Week Range$35.12▼$64.16Volume8.04 million shsAverage Volume11.36 million shsMarket Capitalization$174.67 billionP/E Ratio9.56Dividend Yield2.10%Price Target$59.44Consensus RatingHold Company Overview Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care. Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products. The company also develops treatments for rare blood disorders, including hemophilia, and hormone-related conditions such as growth disorders. The company traces its history to the development of insulin production in Denmark during the 1920s. Novo Nordisk was formed in 1989 through the merger of Nordisk Gentofte and Novo Industri. Its products are marketed internationally, with operations and commercial activities serving patients and health care providers across numerous regions, including North America, Europe, Asia and other global markets.AI Generated. May Contain Errors. Read More Novo Nordisk A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreNVO MarketRank™: 4.03426791277 of 5 starsNovo Nordisk A/S scored higher than 81% of companies evaluated by MarketBeat, and ranked 80th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 5 buy ratings, 16 hold ratings, and 5 sell ratings.Upside PotentialNovo Nordisk A/S has a consensus price target of $59.44, representing about 51.9% upside from its current price of $39.12.Amount of Analyst CoverageNovo Nordisk A/S has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novo Nordisk A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Novo Nordisk A/S are expected to remain at $3.42 per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 9.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 9.56, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.36.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 5.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novo Nordisk A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.84% of the float of Novo Nordisk A/S has been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 3.11, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novo Nordisk A/S has recently increased by 18.38%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovo Nordisk A/S pays a meaningful dividend of 2.09%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovo Nordisk A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 20.05%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.98% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.Read more about Novo Nordisk A/S's dividend. News and Social Media2.9 / 5News Sentiment0.62 News SentimentNovo Nordisk A/S has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Novo Nordisk A/S this week, compared to 7 articles on an average week.Search InterestOnly 46 people have searched for NVO on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat Follows29 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 123% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by Insiders0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by Institutions11.54% of the stock of Novo Nordisk A/S is held by institutions.Read more about Novo Nordisk A/S's insider trading history. Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVO Stock News HeadlinesEli Lilly can continue Zepbound ads despite Novo Nordisk’s claims over weight-loss drug comparisonsOctober 27 at 2:07 AM | msn.comNovo Nordisk denied injunction against Eli Lilly's advertisingOctober 27 at 2:07 AM | marketscreener.comM80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports to the U.S. With a January 1, 2027 deadline approaching, the Pentagon selected four companies to build critical mineral processing facilities on U.S. military bases. Only one was chosen for heavy rare earths - a Nasdaq-listed firm with an Ohio metallurgy facility under Pentagon contracts and rights to 80% of output from a major Canadian processing plant.October 27 at 1:00 AM | The Tomorrow Investor (Ad)US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo NordiskOctober 26 at 9:07 PM | msn.comNovo Nordisk A/S reports share repurchase transactions under DKK 15 billion programmeOctober 26 at 3:47 PM | msn.comNovo Nordisk A/S - share repurchase programmeOctober 26 at 3:47 PM | finance.yahoo.comBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts (NVO)MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.October 26 at 8:35 AM | marketbeat.comOnly 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI (NVO)Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.October 15, 2026 | marketbeat.comSee More Headlines NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed this year? Novo Nordisk A/S's stock was trading at $50.88 on January 1st, 2026. Since then, NVO stock has decreased by 23.1% and is now trading at $39.12. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Tuesday, June, 30th. The company reported $0.94 earnings per share for the quarter. The business earned $11.98 billion during the quarter. Novo Nordisk A/S had a trailing twelve-month return on equity of 58.61% and a net margin of 35.36%. When did Novo Nordisk A/S's stock split? Shares of Novo Nordisk A/S split before market open on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly minted shares were issued to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Novo Nordisk A/S have any subsidiaries? Novo Nordisk A/S subsidiaries include these companies: Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and others. Who are Novo Nordisk A/S's major shareholders? Novo Nordisk A/S's top institutional shareholders include Euro Pacific Asset Management LLC (0.01%), QV Investors Inc. (0.01%), Cantor Fitzgerald Investment Advisors L.P. (0.01%) and Cantor Fitzgerald Investment Advisors L.P. (0.01%). View institutional ownership trends. How do I buy shares of Novo Nordisk A/S? Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Eli Lilly and Company (LLY), Tesla (TSLA), Broadcom (AVGO), Palantir Technologies (PLTR) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings6/30/2026Record date for 8/25 Dividend8/17/2026Ex-Dividend for 8/25 Dividend8/17/2026Dividend Payable8/25/2026Today10/27/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NVO's financial health is in the Yellow zone, according to TradeSmith. NVO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NVO CIK353278 Webwww.novonordisk.com Phone(454) 444-8888Fax45-4449-0555Employees69,505Year Founded1923Price Target and Rating Average Price Target for Novo Nordisk A/S$59.44 High Price Target$175.00 Low Price Target$38.00 Potential Upside/Downside+51.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$4.09 Trailing P/E Ratio9.56 Forward P/E Ratio11.44 P/E Growth1.33Net Income$15.51 billion Net Margins35.36% Pretax Margin45.31% Return on Equity58.61% Return on Assets20.91% Debt Debt-to-Equity Ratio0.55 Current Ratio0.87 Quick Ratio0.66 Sales & Book Value Annual Sales$46.80 billion Price / Sales3.73 Cash Flow$4.70 per share Price / Cash Flow8.33 Book Value$6.58 per share Price / Book5.95Miscellaneous Outstanding Shares4,465,000,000Free Float4,461,875,000Market Cap$174.67 billion OptionableOptionable Beta0.76 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:NVO) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
